Pediatric Dupixent approval tops dermatology FDA news in 2020
Click Here to Manage Email Alerts
The FDA approved drugs and products for many dermatological diseases and conditions in 2020. Here are some of the top-read articles on Healio regarding this year’s dermatology FDA approvals.
FDA approves Dupixent for atopic dermatitis in children
Dupixent has been approved by the FDA for the treatment of moderate to severe atopic dermatitis in children aged 6 to 11 years. Read more.
FDA approves Winlevi for acne treatment
Winlevi (clascoterone cream 1%) is a topical androgen receptor inhibitor that limits hormones from increasing sebum production and inflammation. Read more.
FDA approves Taltz for pediatric psoriasis
The FDA has approved a supplemental biologics license application for ixekizumab in pediatric patients with moderate to severe plaque psoriasis. Read more.
FDA approves Wynzora cream for plaque psoriasis
Wynzora cream (calcipotriene and betamethasone dipropionate, w/w 0.005%/0.064%) is based on PAD technology, which enables stability of both drugs in an aqueous formulation. Read more.
FDA approves triamcinolone acetonide ointment
Triamcinolone acetonide ointment USP 0.05% was approved for the treatment of inflammatory and pruritic manifestations of dermatoses. Read more.
FDA approves topical foam for rosacea in adults
Zilxi (minocycline topical foam 1.5%) is the first minocycline product to be approved by the FDA for use in rosacea. Read more.
FDA approves Nevisense 3.0 for melanoma detection
The third generation of the Nevisense platform is a more streamlined, efficient version of the system that was previously approved by the FDA. Read more.
FDA approves Dupixent prefilled pen
The single-dose, prefilled pen contains 300 mg of Dupixent (dupilumab) and has been approved by the FDA for all Dupixent indications in patients aged 12 years and older. Read more.
FDA approves Jublia for onychomycosis in children
Jublia (efinaconazole topical solution 10%) is indicated for the treatment of onychomycosis and was first approved for individuals 18 years and older in June 2014. Read more.